Alzamend’s AL001 Reduces Myo-Inositol in 17 of 18 Regions, Spares Glutamate
In a six-subject Phase II MRS study, two weeks of AL001 dosing showed reduction of myo-inositol in 17 of 18 brain regions versus eight regions with lithium carbonate. AL001 produced minimal glutamate changes in 10 regions versus widespread lithium disruption, suggesting a distinct neurochemical footprint and potential tolerability advantage.
1. Trial Design and Dosing
Alzamend conducted a two-week Phase II pharmacodynamic study using brain magnetic resonance spectroscopy in six healthy subjects to compare blood bioequivalent doses of AL001 with lithium carbonate across 18 brain regions.
2. Distinct Neurochemical Footprint
AL001 and lithium carbonate produced opposite trends in multiple metabolites, with AL001 trending downward where lithium trended upward, indicating a potentially less disruptive effect on healthy brain tissue.
3. Myo-Inositol Reduction Coverage
Both compounds reduced levels of myo-inositol, but AL001 affected this biomarker in 17 of 18 regions versus eight regions for lithium carbonate, suggesting broader engagement of lithium’s core mechanism of action.
4. Glutamate Homeostasis Potential
AL001 preserved glutamate levels in 10 of 18 regions compared to disruptions across all regions with lithium carbonate, implying a potential tolerability advantage for long-term treatment.